Researchers investigated how tumor-specific murine CD8+ T cells and human tumor infiltrating lymphocytes were impacted when expanded ex vivo with the TLR9 agonist CpG.
[Journal For Immunotherapy of Cancer]
Sorry, but the selected Zotpress account can't be found.